STOCK TITAN

InMed Announces Election of Directors

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

On November 24, 2020, InMed Pharmaceuticals confirmed the successful election of its director nominees during the annual general meeting held on November 20, 2020. Shareholders approved all proposed matters, including the election of directors to serve until the next annual meeting. Notable voting percentages include Eric A. Adams with 90.84% and Adam Cutler with 93.01% in favor. InMed is focused on developing cannabinoid-based medications, particularly targeting diseases with high unmet medical needs.

Positive
  • All proposed matters approved by shareholders.
  • High approval percentages for director nominees, indicating strong shareholder support.
Negative
  • None.

VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today confirmed that, at its annual general and special meeting of shareholders held on November 20, 2020 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 7, 2020, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

Director

Votes For


Withheld Votes

Number

Percentage


Number

Percentage

Eric A. Adams

639,176

90.84%


64,464

9.16%

Adam Cutler

654,431

93.01%


49,209

6.99%

William J. Garner

644,945

91.66%


58,695

8.34%

Andrew Hull

654,149

92.97%


49,491

7.03%

Catherine Sazdanoff

653,532

92.88%


50,108

7.12%

InMed filed a report of voting results on SEDAR at www.sedar.com on November 24, 2020.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of CBN; developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cision View original content:http://www.prnewswire.com/news-releases/inmed-announces-election-of-directors-301180215.html

SOURCE InMed Pharmaceuticals Inc.

FAQ

What was the outcome of InMed Pharmaceuticals' annual meeting on November 20, 2020?

All proposed matters, including the election of directors, were approved by shareholders.

Who were the directors elected by InMed Pharmaceuticals on November 20, 2020?

The directors elected include Eric A. Adams, Adam Cutler, William J. Garner, Andrew Hull, and Catherine Sazdanoff.

What percentage of votes did Eric A. Adams receive during the election?

Eric A. Adams received 90.84% of the votes in favor.

What is InMed Pharmaceuticals focusing on in its development?

InMed Pharmaceuticals is focused on developing cannabinoid-based medications, especially cannabinol (CBN) for diseases with high unmet medical needs.

Where can I find more information about InMed Pharmaceuticals?

More information can be found on InMed Pharmaceuticals' website at www.inmedpharma.com.

Inmed Pharmaceuticals Inc

NASDAQ:INM

INM Rankings

INM Latest News

INM Stock Data

4.02M
720.04k
0.87%
Biotechnology
Pharmaceutical Preparations
Link
Canada
VANCOUVER